Cargando…
Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease
BACKGROUND: Prospectively and systematically collected long-term real-world clinical data on ustekinumab (anti-interleukin-12/23) are still scarce. AIMS: To assess the long-term effectiveness of ustekinumab in patients with active Crohn’s disease (CD). METHODS: This is a prospective multicenter stud...
Autores principales: | Forss, Anders, Clements, Mark, Myrelid, Pär, Strid, Hans, Söderman, Charlotte, Wagner, Agnieszka, Andersson, David, Hjelm, Fredrik, Olén, Ola, Halfvarson, Jonas, Ludvigsson, Jonas F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883312/ https://www.ncbi.nlm.nih.gov/pubmed/35459973 http://dx.doi.org/10.1007/s10620-022-07501-z |
Ejemplares similares
-
Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022) -
Validating surgical procedure codes for inflammatory bowel disease in the Swedish National Patient Register
por: Forss, Anders, et al.
Publicado: (2019) -
Probability of Stoma in Incident Patients With Crohn’s Disease in Sweden 2003-2019: A Population-based Study
por: Everhov, Åsa H, et al.
Publicado: (2021) -
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023) -
Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study
por: Everhov, Åsa H, et al.
Publicado: (2020)